PT2766040T - Pertuzumab, trastuzumab, docetaxel e carboplatina para o tratamento do cancro da mama em fase precoce - Google Patents

Pertuzumab, trastuzumab, docetaxel e carboplatina para o tratamento do cancro da mama em fase precoce

Info

Publication number: PT2766040T
Authority: PT; Portugal
Prior art keywords: pertuzumab; trastuzumab; docetaxel; carboplatin; early
Prior art date: 2011-10-14

Application number

PT12778010T

Other languages

English (en)

Inventor

Alavattam Sreedhara

C Amler Lukas

C Benyunes Mark

L Clark Emma

H De Toledo Pelizon Christina

W Kwong Glover Zephania

Mitchell Lada

Ratnayake Jayantha

A Ross Graham

Walker Ru-Amir

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-14

Filing date

2012-10-11

Publication date

2019-07-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47073543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2766040(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-10-11 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2019-07-11 Publication of PT2766040T publication Critical patent/PT2766040T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Packages (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PT12778010T 2011-10-14 2012-10-11 Pertuzumab, trastuzumab, docetaxel e carboplatina para o tratamento do cancro da mama em fase precoce PT2766040T (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date
US201161547535P	2011-10-14	2011-10-14
US201161567015P	2011-12-05	2011-12-05
US201261657669P	2012-06-08	2012-06-08
US201261682037P	2012-08-10	2012-08-10
US201261694584P	2012-08-29	2012-08-29

Publications (1)

Publication Number	Publication Date
PT2766040T true PT2766040T (pt)	2019-07-11

Family

ID=47073543

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PT12778010T PT2766040T (pt)	2011-10-14	2012-10-11	Pertuzumab, trastuzumab, docetaxel e carboplatina para o tratamento do cancro da mama em fase precoce
PT231727942T PT4234033T (pt)	2011-10-14	2012-10-11	Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
PT241746379T PT4403228T (pt)	2011-10-14	2012-10-11	Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
PT231728478T PT4241849T (pt)	2011-10-14	2012-10-11	Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
PT231727942T PT4234033T (pt)	2011-10-14	2012-10-11	Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
PT241746379T PT4403228T (pt)	2011-10-14	2012-10-11	Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
PT231728478T PT4241849T (pt)	2011-10-14	2012-10-11	Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo

Country Status (30)

Country	Link
US (9)	US20130095172A1 (pt)
EP (7)	EP3598981A3 (pt)
JP (8)	JP2014530235A (pt)
KR (5)	KR102502545B1 (pt)
CN (8)	CN117018187A (pt)
AU (4)	AU2012322797B2 (pt)
BR (1)	BR112014007521A8 (pt)
CL (1)	CL2014000889A1 (pt)
DK (4)	DK4403228T3 (pt)
EA (1)	EA034390B1 (pt)
ES (4)	ES3023516T3 (pt)
FI (3)	FI4403228T3 (pt)
HK (1)	HK1202242A1 (pt)
HR (1)	HRP20191247T1 (pt)
HU (1)	HUE044352T2 (pt)
IL (5)	IL309917A (pt)
IN (1)	IN2014CN02703A (pt)
LT (4)	LT4403228T (pt)
MX (2)	MX2014004021A (pt)
MY (2)	MY194408A (pt)
PE (1)	PE20142363A1 (pt)
PH (2)	PH12014500733B1 (pt)
PL (4)	PL4234033T3 (pt)
PT (4)	PT2766040T (pt)
RS (1)	RS58944B1 (pt)
SG (3)	SG10201606756PA (pt)
SI (4)	SI4234033T1 (pt)
UA (2)	UA123092C2 (pt)
WO (1)	WO2013055874A2 (pt)
ZA (1)	ZA201401259B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
CN103251946A (zh)	2005-02-23	2013-08-21	健泰科生物技术公司	使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
PE20090681A1 (es)	2007-03-02	2009-06-10	Genentech Inc	Prediccion de respuesta a un inhibidor her
US9901567B2 (en)	2007-08-01	2018-02-27	Syntarga B.V.	Substituted CC-1065 analogs and their conjugates
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt)	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
AU2009320481C1 (en)	2008-11-03	2016-12-08	Syntarga B.V.	Novel CC-1065 analogs and their conjugates
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
PT3056203T (pt)	2010-04-21	2018-02-15	Syntarga Bv	Conjugados de análogos de cc-1065 e ligantes bifuncionais
DK4403228T3 (da)	2011-10-14	2025-10-13	Hoffmann La Roche	Anvendelser for og fremstillet artikel indbefattende HER2-dimeriseringshæmmeren pertuzumab
AR094403A1 (es)	2013-01-11	2015-07-29	Hoffmann La Roche	Terapia de combinación de anticuerpos anti-her3
RU2737727C2 (ru)	2013-04-16	2020-12-02	Дженентек, Инк.	Варианты пертузумаба и их аналитическая характеристика
EA031077B1 (ru) *	2013-06-19	2018-11-30	Серагон Фармасьютикалз, Инк.	Модулятор рецептора эстрогена и его применения
KR102630750B1 (ko)	2013-12-17	2024-01-30	제넨테크, 인크.	Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
CN104726462A (zh) *	2013-12-20	2015-06-24	北京天广实生物技术股份有限公司	抗her2人源化抗体mil41、其制备方法及用途
JP6342517B2 (ja)	2014-01-10	2018-06-13	シントン・バイオファーマシューティカルズ・ビー．ブイ．ＳｙｎｔｈｏｎＢｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓＢ．Ｖ．	改善されたインビボ抗腫瘍活性を示すデュオカルマイシンａｄｃ
KR20220045075A (ko) *	2014-01-10	2022-04-12	비온디스 비.브이.	자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc
EP3092010B1 (en)	2014-01-10	2018-07-11	Synthon Biopharmaceuticals B.V.	Method for purifying cys-linked antibody-drug conjugates
WO2016094341A1 (en) *	2014-12-08	2016-06-16	Synta Pharmaceuticals Corp.	Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer
CN108027360A (zh) *	2015-05-29	2018-05-11	爱科谱迅病理研究公司	用于最优癌症治疗的定量Her2蛋白质
CA2986263A1 (en)	2015-06-17	2016-12-22	Genentech, Inc.	Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
CN107531788B (zh)	2015-06-24	2022-06-21	豪夫迈·罗氏有限公司	对her2和血脑屏障受体特异性的三特异性抗体及使用方法
MA45324A (fr)	2016-03-15	2019-01-23	Seattle Genetics Inc	Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
EP3534948A1 (en) *	2016-11-04	2019-09-11	Genentech, Inc.	Treatment of her2-positive breast cancer
AU2017387909A1 (en) *	2016-12-28	2019-06-27	Genentech, Inc.	Treatment of advanced HER2 expressing cancer
TW202508629A (zh)	2017-01-17	2025-03-01	美商建南德克公司	皮下her2抗體調配物
KR20230144110A (ko)	2017-03-02	2023-10-13	제넨테크, 인크.	Her2-양성 유방암 어쥬번트 치료
KR102267593B1 (ko) *	2018-10-19	2021-06-21	주식회사 프로티나	Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법
AU2020207962A1 (en) *	2019-01-18	2021-07-22	University Of Southern California	Methods and compositions to improve the safety and efficacy of cellular therapies
MX2021014540A (es) *	2019-05-27	2022-04-12	Tolmar International Ltd	Composiciones de acetato de leuprolida y metodos para usar las mismas para tratar cancer de mama.
EP3990041B1 (en) *	2019-06-28	2025-08-06	Board of Regents, The University of Texas System	Method of reconstituting liposomal annamycin
WO2020264160A1 (en)	2019-06-28	2020-12-30	Donald Picker	Preparation of preliposomal annamycin lyophilizate
AU2020381495A1 (en) *	2019-11-15	2022-05-19	Seagen Inc.	Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate
US20230175069A1 (en) *	2020-04-29	2023-06-08	University Of Pittsburgh-Of The Commonweal Th System Of Higher Education	Compositions and methods for detecting gene fusions of esr1 and ccdc170 for determining increased resistance to endocrine therapy and for cancer treatment
CN111710425A (zh) *	2020-06-19	2020-09-25	复旦大学附属中山医院	一种免疫检查点抑制剂心脏毒性评估方法，系统及装置
JP2023532122A (ja) *	2020-06-29	2023-07-26	ジェネンテック，インコーポレイテッド	ペルツズマブにトラスツズマブを加えた固定用量配合剤
JP2024543621A (ja) *	2021-12-07	2024-11-21	アイオーセラピューティクスインコーポレイテッド	Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストおよびタキサンの使用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
EP0491675A1 (en)	1984-01-30	1992-06-24	Imperial Cancer Research Technology Limited	Improvements relating to growth factors
US5401638A (en)	1986-06-04	1995-03-28	Oncogene Science, Inc.	Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en)	1986-12-31	1990-11-06	The Regents Of The University Of California	Determination of status in neoplastic disease
US5720937A (en)	1988-01-12	1998-02-24	Genentech, Inc.	In vivo tumor detection assay
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DK0474727T3 (da)	1989-05-19	1998-01-12	Genentech Inc	HER2 ekstracellulært domæne
WO1991005264A1 (en)	1989-09-29	1991-04-18	Oncogenetics Partners	Detection and quantification of neu related proteins in the biological fluids of humans
US5183884A (en)	1989-12-01	1993-02-02	United States Of America	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
WO1993006217A1 (en)	1991-09-19	1993-04-01	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
MX9800684A (es)	1995-07-27	1998-04-30	Genentech Inc	Formulacion de proteinas liofilizadas isotonicas estables.
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
US7371376B1 (en)	1996-10-18	2008-05-13	Genentech, Inc.	Anti-ErbB2 antibodies
EP0852951A1 (de)	1996-11-19	1998-07-15	Roche Diagnostics GmbH	Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
JP4031049B2 (ja)	1996-11-27	2008-01-09	ジェネンテック，インコーポレーテッド	タンパク質精製
US5994071A (en)	1997-04-04	1999-11-30	Albany Medical College	Assessment of prostate cancer
ZA9811162B (en)	1997-12-12	2000-06-07	Genentech Inc	Treatment with anti-ERBB2 antibodies.
AU765003B2 (en)	1998-03-27	2003-09-04	Genentech Inc.	Apo-2 ligand-anti-her-2 antibody synergism
ATE321066T1 (de)	1998-05-06	2006-04-15	Genentech Inc	Anti-her2 antikörperzusammensetzung
US6573043B1 (en)	1998-10-07	2003-06-03	Genentech, Inc.	Tissue analysis and kits therefor
EP1187632B1 (en)	1999-05-14	2008-12-03	Genentech, Inc.	TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US20030086924A1 (en)	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
CA2383493C (en)	1999-06-25	2010-08-10	Genentech, Inc.	Treating prostate cancer with anti-erbb2 antibodies
US20040013667A1 (en)	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
GEP20104998B (en)	1999-06-25	2010-06-10	Genentech Inc	Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
EP2111870A1 (en)	1999-08-27	2009-10-28	Genentech, Inc.	Dosages for treatment of anti-erbB2 antibodies
US7097840B2 (en)	2000-03-16	2006-08-29	Genentech, Inc.	Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en)	2000-03-16	2003-10-14	Genentech, Inc.	Rodent HER2 tumor model
IL152656A0 (en)	2000-05-19	2003-06-24	Genentech Inc	Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6984494B2 (en)	2000-08-15	2006-01-10	Genentech, Inc.	Analytical method
KR20030074693A (ko)	2000-12-28	2003-09-19	알투스 바이올로직스 인코포레이티드	전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
ES2401428T3 (es)	2002-04-10	2013-04-19	Genentech, Inc.	Variantes de anticuerpos anti-HER2
EP2263691B1 (en)	2002-07-15	2012-08-29	F.Hoffmann-La Roche Ag	Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
AU2003265994B2 (en)	2002-09-11	2010-04-01	Genentech, Inc.	Protein purification
US20060100168A1 (en) *	2002-09-30	2006-05-11	The Trustee Of Boston University	Method of treating cancer using adenosine and its analogs
CA2506320A1 (en)	2002-11-21	2004-06-10	Genentech, Inc.	Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
PL3095793T3 (pl)	2003-07-28	2020-09-07	Genentech, Inc.	Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A
JP4969440B2 (ja)	2004-04-08	2012-07-04	デビッド，ビー．エイガス，	疼痛治療のためのＥｒｂＢアンタゴニスト
MXPA06014065A (es)	2004-06-01	2007-01-31	Genentech Inc	Conjugados de droga-anticuerpo y metodos.
SV2006002143A (es)	2004-06-16	2006-01-26	Genentech Inc	Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US20050280299A1 (en)	2004-06-18	2005-12-22	Alfmeier Corporation	Mounting adaptor for seat assembly, and seat assembly having mounting adaptor
AU2005287404B2 (en)	2004-07-22	2009-05-07	Genentech, Inc.	HER2 antibody composition
WO2006031370A2 (en)	2004-08-19	2006-03-23	Genentech, Inc.	Polypeptide variants with altered effector function
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
BRPI0515735A2 (pt) *	2004-11-04	2011-10-11	Pfizer Prod Inc	tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos
AU2005314127A1 (en)	2004-12-07	2006-06-15	Genentech, Inc.	Selecting patients for therapy with a HER inhibitor
MX2007008768A (es)	2005-01-21	2007-10-19	Genentech Inc	Dosificacion fija de anticuerpos her.
SG166775A1 (en) *	2005-02-18	2010-12-29	Abraxis Bioscience Llc	Combinations and modes of administration of therapeutic agents and combination therapy
CN103251946A (zh)	2005-02-23	2013-08-21	健泰科生物技术公司	使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
TW200642695A (en)	2005-03-08	2006-12-16	Genentech Inc	Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
US20060212956A1 (en)	2005-03-14	2006-09-21	Genentech, Inc.	Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja)	2005-05-13	2006-11-24	Genentech Inc	Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
MY157955A (en)	2005-07-06	2016-08-30	Hoffmann La Roche	Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es)	2005-07-22	2007-03-09	Genentech Inc	Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en)	2005-08-12	2010-04-20	Hoffmann-La Roche Inc.	Method for predicting the response to a treatment
TW200812615A (en)	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
KR20090019890A (ko)	2006-06-05	2009-02-25	제넨테크, 인크.	Ｅｇｆ 또는 ｔｇｆ-알파 수준이 상승된 암 환자의 생존 연장
CN101466468B (zh)	2006-06-14	2012-05-23	株式会社科特拉	排气净化用催化剂
MY150756A (en)	2006-08-21	2014-02-28	Hoffmann La Roche	Tumor theraphy with an anti-vegf antibody
WO2008031531A1 (en)	2006-09-15	2008-03-20	F. Hoffmann-La Roche Ag	Tumor therapy with a combination of anti-her2 antibodies
PE20090681A1 (es) *	2007-03-02	2009-06-10	Genentech Inc	Prediccion de respuesta a un inhibidor her
US8529901B2 (en)	2007-06-06	2013-09-10	Hoffmann-La Roche, Inc.	Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
US9551033B2 (en)	2007-06-08	2017-01-24	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2417148T3 (es)	2007-06-08	2013-08-06	Genentech, Inc.	Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
TWI471134B (zh)	2007-09-12	2015-02-01	Genentech Inc	肌醇磷脂３－激酶抑制劑化合物及化療劑之組合及使用方法
EP2211854A4 (en) *	2007-10-19	2011-01-12	Bipar Sciences Inc	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
CL2008003218A1 (es)	2007-10-30	2009-03-06	Genentech Inc	Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante.
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US20090203015A1 (en) *	2008-02-13	2009-08-13	Celera Corporation	Multiplex assays for hormonal and growth factor receptors, and uses thereof
US20090226455A1 (en)	2008-03-06	2009-09-10	Genentech, Inc.	Combination therapy with c-met and her antagonists
HUE025507T2 (en)	2008-03-18	2016-02-29	Genentech Inc	Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
BRPI0812682A2 (pt) *	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
KR20170015525A (ko) *	2008-11-22	2017-02-08	제넨테크, 인크.	유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
SG10201507044PA (en)	2009-05-29	2015-10-29	Hoffmann La Roche	Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110165155A1 (en) *	2009-12-04	2011-07-07	Genentech, Inc.	Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
DK4403228T3 (da)	2011-10-14	2025-10-13	Hoffmann La Roche	Anvendelser for og fremstillet artikel indbefattende HER2-dimeriseringshæmmeren pertuzumab

2012
- 2012-10-11 DK DK24174637.9T patent/DK4403228T3/da active
- 2012-10-11 SG SG10201606756PA patent/SG10201606756PA/en unknown
- 2012-10-11 IL IL309917A patent/IL309917A/en unknown
- 2012-10-11 EP EP19165341.9A patent/EP3598981A3/en not_active Withdrawn
- 2012-10-11 EP EP25181690.6A patent/EP4635572A2/en active Pending
- 2012-10-11 CN CN202310820523.XA patent/CN117018187A/zh active Pending
- 2012-10-11 SI SI201232088T patent/SI4234033T1/sl unknown
- 2012-10-11 IN IN2703CHN2014 patent/IN2014CN02703A/en unknown
- 2012-10-11 FI FIEP24174637.9T patent/FI4403228T3/fi active
- 2012-10-11 PT PT12778010T patent/PT2766040T/pt unknown
- 2012-10-11 KR KR1020177004681A patent/KR102502545B1/ko active Active
- 2012-10-11 FI FIEP23172847.8T patent/FI4241849T3/fi active
- 2012-10-11 IL IL301603A patent/IL301603A/en unknown
- 2012-10-11 ES ES23172794T patent/ES3023516T3/es active Active
- 2012-10-11 US US13/649,591 patent/US20130095172A1/en not_active Abandoned
- 2012-10-11 PE PE2014000507A patent/PE20142363A1/es active IP Right Grant
- 2012-10-11 SI SI201232077T patent/SI4241849T1/sl unknown
- 2012-10-11 DK DK12778010.4T patent/DK2766040T3/da active
- 2012-10-11 ES ES12778010T patent/ES2736005T3/es active Active
- 2012-10-11 SG SG10202110077Q patent/SG10202110077QA/en unknown
- 2012-10-11 ES ES24174637T patent/ES3045013T3/es active Active
- 2012-10-11 HU HUE12778010 patent/HUE044352T2/hu unknown
- 2012-10-11 MX MX2014004021A patent/MX2014004021A/es active IP Right Grant
- 2012-10-11 CN CN201280061896.3A patent/CN104334189A/zh active Pending
- 2012-10-11 HK HK15102729.7A patent/HK1202242A1/xx unknown
- 2012-10-11 EP EP23172847.8A patent/EP4241849B1/en active Active
- 2012-10-11 FI FIEP23172794.2T patent/FI4234033T3/fi active
- 2012-10-11 EP EP23172794.2A patent/EP4234033B1/en active Active
- 2012-10-11 PL PL23172794.2T patent/PL4234033T3/pl unknown
- 2012-10-11 PH PH1/2014/500733A patent/PH12014500733B1/en unknown
- 2012-10-11 CN CN202310108240.2A patent/CN116271013A/zh active Pending
- 2012-10-11 PT PT231727942T patent/PT4234033T/pt unknown
- 2012-10-11 WO PCT/US2012/059683 patent/WO2013055874A2/en not_active Ceased
- 2012-10-11 PL PL12778010T patent/PL2766040T3/pl unknown
- 2012-10-11 CN CN202310701159.5A patent/CN116808199A/zh active Pending
- 2012-10-11 PL PL24174637.9T patent/PL4403228T3/pl unknown
- 2012-10-11 DK DK23172794.2T patent/DK4234033T3/da active
- 2012-10-11 JP JP2014535859A patent/JP2014530235A/ja not_active Withdrawn
- 2012-10-11 KR KR1020147009738A patent/KR102099991B1/ko active Active
- 2012-10-11 CN CN202310064889.9A patent/CN116271011B/zh active Active
- 2012-10-11 MY MYPI2019003795A patent/MY194408A/en unknown
- 2012-10-11 SG SG11201401432XA patent/SG11201401432XA/en unknown
- 2012-10-11 LT LTEP24174637.9T patent/LT4403228T/lt unknown
- 2012-10-11 BR BR112014007521A patent/BR112014007521A8/pt not_active Application Discontinuation
- 2012-10-11 LT LTEP23172847.8T patent/LT4241849T/lt unknown
- 2012-10-11 EP EP23172860.1A patent/EP4234034A3/en not_active Withdrawn
- 2012-10-11 LT LTEP12778010.4T patent/LT2766040T/lt unknown
- 2012-10-11 CN CN201811518146.XA patent/CN109908341B/zh active Active
- 2012-10-11 KR KR1020237015216A patent/KR102770098B1/ko active Active
- 2012-10-11 KR KR1020237005562A patent/KR102679155B1/ko active Active
- 2012-10-11 LT LTEP23172794.2T patent/LT4234033T/lt unknown
- 2012-10-11 CN CN202210486683.0A patent/CN114984205A/zh active Pending
- 2012-10-11 DK DK23172847.8T patent/DK4241849T3/da active
- 2012-10-11 SI SI201231637T patent/SI2766040T1/sl unknown
- 2012-10-11 HR HRP20191247TT patent/HRP20191247T1/hr unknown
- 2012-10-11 EA EA201490779A patent/EA034390B1/ru active Protection Beyond IP Right Term
- 2012-10-11 EP EP12778010.4A patent/EP2766040B1/en not_active Revoked
- 2012-10-11 MY MYPI2014001060A patent/MY172326A/en unknown
- 2012-10-11 PL PL23172847.8T patent/PL4241849T3/pl unknown
- 2012-10-11 EP EP24174637.9A patent/EP4403228B1/en active Active
- 2012-10-11 KR KR1020247021013A patent/KR20240109285A/ko active Pending
- 2012-10-11 PT PT241746379T patent/PT4403228T/pt unknown
- 2012-10-11 UA UAA201709999A patent/UA123092C2/uk unknown
- 2012-10-11 ES ES23172847T patent/ES2993341T3/es active Active
- 2012-10-11 PT PT231728478T patent/PT4241849T/pt unknown
- 2012-10-11 RS RS20190845A patent/RS58944B1/sr unknown
- 2012-10-11 SI SI201232097T patent/SI4403228T1/sl unknown
- 2012-10-11 AU AU2012322797A patent/AU2012322797B2/en active Active
- 2012-10-11 CN CN202310135044.4A patent/CN116236569A/zh active Pending
- 2012-11-10 UA UAA201405091A patent/UA116095C2/uk unknown
2014
- 2014-02-19 ZA ZA2014/01259A patent/ZA201401259B/en unknown
- 2014-03-06 IL IL231350A patent/IL231350B2/en unknown
- 2014-04-03 MX MX2019009153A patent/MX2019009153A/es unknown
- 2014-04-09 CL CL2014000889A patent/CL2014000889A1/es unknown
2016
- 2016-03-02 US US15/058,520 patent/US20160175438A1/en not_active Abandoned
- 2016-07-15 AU AU2016204962A patent/AU2016204962B2/en active Active
2017
- 2017-06-28 JP JP2017125883A patent/JP2017222663A/ja not_active Withdrawn
2018
- 2018-06-05 AU AU2018203970A patent/AU2018203970B2/en active Active
- 2018-09-06 US US16/123,809 patent/US20190117769A1/en not_active Abandoned
2019
- 2019-03-11 PH PH12019500519A patent/PH12019500519A1/en unknown
- 2019-10-02 JP JP2019182187A patent/JP6646785B1/ja active Active
- 2019-11-04 AU AU2019261666A patent/AU2019261666B2/en active Active
2020
- 2020-01-10 JP JP2020002531A patent/JP2020090507A/ja not_active Withdrawn
- 2020-02-20 US US16/796,163 patent/US20200206348A1/en not_active Abandoned
- 2020-08-13 US US16/992,966 patent/US20210015919A1/en not_active Abandoned
- 2020-08-17 US US16/994,950 patent/US20200376120A1/en not_active Abandoned
2021
- 2021-10-03 IL IL286921A patent/IL286921A/en unknown
2022
- 2022-01-06 JP JP2022000876A patent/JP2022062010A/ja not_active Withdrawn
- 2022-03-28 US US17/656,732 patent/US20220362379A1/en not_active Abandoned
2023
- 2023-04-28 US US18/309,488 patent/US20230277664A1/en not_active Abandoned
- 2023-04-28 US US18/309,452 patent/US20230277663A1/en active Pending
- 2023-05-01 JP JP2023075388A patent/JP7303957B1/ja active Active
- 2023-05-01 JP JP2023075391A patent/JP7352760B2/ja active Active
- 2023-09-15 JP JP2023150231A patent/JP2024009803A/ja not_active Withdrawn
2025
- 2025-09-25 IL IL323574A patent/IL323574A/en unknown

Also Published As

Publication number	Publication date
KR102099991B1 (ko)	2020-04-14
US20200376120A1 (en)	2020-12-03
CL2014000889A1 (es)	2014-07-25
KR20230073340A (ko)	2023-05-25
HRP20191247T1 (hr)	2019-10-18
ES2993341T3 (en)	2024-12-27
CN104334189A (zh)	2015-02-04
CN114984205A (zh)	2022-09-02
IL323574A (en)	2025-11-01
FI4403228T3 (fi)	2025-10-15
EP4241849A2 (en)	2023-09-13
AU2016204962B2 (en)	2018-03-08
AU2018203970B2 (en)	2019-11-21
CN116271013A (zh)	2023-06-23
JP2024009803A (ja)	2024-01-23
PH12019500519A1 (en)	2021-06-14
LT4234033T (lt)	2025-04-10
US20200206348A1 (en)	2020-07-02
US20190117769A1 (en)	2019-04-25
BR112014007521A2 (pt)	2017-12-12
SG10201606756PA (en)	2016-10-28
NZ621367A (en)	2016-04-29
EP4635572A2 (en)	2025-10-22
WO2013055874A3 (en)	2013-06-20
AU2012322797A1 (en)	2014-03-20
HUE044352T2 (hu)	2019-10-28
KR20240109285A (ko)	2024-07-10
US20160175438A1 (en)	2016-06-23
US20210015919A1 (en)	2021-01-21
PH12014500733A1 (en)	2014-06-30
UA116095C2 (uk)	2018-02-12
MX2019009153A (es)	2019-10-14
IL301603A (en)	2023-05-01
PL4234033T3 (pl)	2025-04-28
JP2020033353A (ja)	2020-03-05
FI4241849T3 (fi)	2024-11-12
ES3023516T3 (en)	2025-06-02
AU2019261666B2 (en)	2021-08-05
KR102679155B1 (ko)	2024-06-28
EP4234033B1 (en)	2025-01-29
JP2022062010A (ja)	2022-04-19
PL4403228T3 (pl)	2025-11-03
JP2014530235A (ja)	2014-11-17
EP4403228A3 (en)	2024-10-23
PH12014500733B1 (en)	2019-07-17
PT4241849T (pt)	2024-10-30
AU2012322797B2 (en)	2016-04-21
KR20230028585A (ko)	2023-02-28
US20220362379A1 (en)	2022-11-17
WO2013055874A2 (en)	2013-04-18
KR20170023195A (ko)	2017-03-02
SI4234033T1 (sl)	2025-05-30
IL231350A0 (en)	2014-04-30
ES2736005T3 (es)	2019-12-23
EP4234033A3 (en)	2023-09-20
EP2766040B1 (en)	2019-05-15
IL231350B1 (en)	2023-04-01
KR102770098B1 (ko)	2025-02-20
CN116271011A (zh)	2023-06-23
IN2014CN02703A (pt)	2015-07-03
CN117018187A (zh)	2023-11-10
US20230277664A1 (en)	2023-09-07
SG10202110077QA (en)	2021-10-28
PE20142363A1 (es)	2015-01-30
EP4403228B1 (en)	2025-07-16
RS58944B1 (sr)	2019-08-30
DK2766040T3 (da)	2019-07-22
HK1202242A1 (en)	2015-09-25
EP2766040A2 (en)	2014-08-20
LT2766040T (lt)	2019-08-12
IL286921A (en)	2021-10-31
US20130095172A1 (en)	2013-04-18
EP4403228A2 (en)	2024-07-24
CN116236569A (zh)	2023-06-09
SG11201401432XA (en)	2014-05-29
MY172326A (en)	2019-11-21
LT4241849T (lt)	2024-11-25
AU2016204962A1 (en)	2016-08-04
CN109908341B (zh)	2023-06-27
EA201490779A1 (ru)	2015-11-30
IL231350B2 (en)	2023-08-01
EA034390B1 (ru)	2020-02-03
DK4403228T3 (da)	2025-10-13
JP7303957B1 (ja)	2023-07-05
EP3598981A2 (en)	2020-01-29
CN116808199A (zh)	2023-09-29
SI4241849T1 (sl)	2025-01-31
EP4234034A3 (en)	2023-09-20
KR102502545B1 (ko)	2023-02-21
JP6646785B1 (ja)	2020-02-14
MX2014004021A (es)	2014-04-30
PL2766040T3 (pl)	2019-11-29
EP3598981A3 (en)	2020-06-10
BR112014007521A8 (pt)	2018-04-10
JP2023109779A (ja)	2023-08-08
JP2023109780A (ja)	2023-08-08
FI4234033T3 (fi)	2025-03-31
JP7352760B2 (ja)	2023-09-28
DK4234033T3 (da)	2025-03-31
EP4241849A3 (en)	2023-09-20
SI4403228T1 (sl)	2025-11-28
PL4241849T3 (pl)	2025-01-13
CN109908341A (zh)	2019-06-21
AU2012322797A8 (en)	2014-06-26
DK4241849T3 (da)	2024-11-18
EP4234034A2 (en)	2023-08-30
EP4234033A2 (en)	2023-08-30
NZ750877A (en)	2020-09-25
SI2766040T1 (sl)	2019-08-30
EP4241849B1 (en)	2024-09-18
KR20140075725A (ko)	2014-06-19
PT4403228T (pt)	2025-10-07
JP2020090507A (ja)	2020-06-11
AU2019261666A1 (en)	2019-11-28
ES3045013T3 (en)	2025-11-27
PT4234033T (pt)	2025-03-20
ZA201401259B (en)	2019-01-30
CN116271011B (zh)	2023-10-27
IL309917A (en)	2024-03-01
AU2018203970A1 (en)	2018-06-21
LT4403228T (lt)	2025-10-27
UA123092C2 (uk)	2021-02-17
US20230277663A1 (en)	2023-09-07
MY194408A (en)	2022-11-30
JP2017222663A (ja)	2017-12-21

Publication	Publication Date	Title
PT2766040T (pt)	2019-07-11	Pertuzumab, trastuzumab, docetaxel e carboplatina para o tratamento do cancro da mama em fase precoce
IL279330A (en)	2021-01-31	Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
IL276434A (en)	2020-09-30	Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
IL237558A0 (en)	2015-04-30	Methods for treating locally advanced breast cancer
SG10201704992SA (en)	2017-07-28	Lsr antibodies, and uses thereof for treatment of cancer
SG2014008304A (en)	2014-06-27	C10rf32 antibodies, and uses thereof for treatment of cancer
EP2751267A4 (en)	2015-01-07	METHOD FOR THE TREATMENT OF BREAST CANCER
GB201117956D0 (en)	2011-11-30	Phytocannabinoids for use in the treatment of breast cancer
IL253947A0 (en)	2017-10-31	Methods of treating breast cancer with taxane therapy
PL3254695T3 (pl)	2021-04-06	Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu
HRP20181757T1 (hr)	2019-01-25	Kombinirana terapija za liječenje raka dojke
EP2755679A4 (en)	2015-09-30	IMMUNOGENS INDUCING CYTOTOXIC T LYMPHOCYTES FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER
IL232340A0 (en)	2014-06-30	lsr antibodies, and their uses for cancer treatment
IL232339A0 (en)	2014-06-30	32rf10c antibodies, and their uses for cancer treatment